Objective To explore the clinical efficacy,metabolic effect and adverse events of recombinant human growth hormone with different acting time in treating children with growth hormone deficiency(GHD).Methods A total of 114 children with GHD were selected and divided into a long acting group[treated with polyethylene glycol recombinant human growth hormone(PEG-rhGH),n=50]and a short acting group[treated with recombinant human growth hormone(rhGH),n=64].General information was collected from two groups of children before treatment.Growth velocity(GV),height standard deviation score(Ht SDS),serum insulin-like growth factor-1(IGF-1),and other serological indicators were compared between two groups at 3rd,6th,9th,and 12th months of treatment.Results After treatment,GV,Ht SDS,and IGF-1 level were increased significantly in two groups of the children with GHD when compared to before treatment(P＜0.05).Ht SDS was higher in long acting group than that in short acting group(P＜0.05).GV and IGF-1 were a little bit higher in long acting group than those in short acting group(P＞0.05).After treatment,all serological indicators of the children in two groups were within the normal ranges,with no statistically significant differences when compared to before treatment(P＞0.05).There were no statistically significant differences in all serological indicators between two groups(P＞0.05).The incidence of adverse events in short acting group was higher than those in the long acting group(P＜0.05).Conclusion Both long-and short-acting rhGH exert significant effects on children with growth hormone deficiency and very little effect on liver and kidney functions,glucose and lipid metabolism,serum proteins and thyroid function,with good safety.Long-acting rhGH can benefit early height gain with low incidence of adverse events during treatment.
growth hormone deficiencyshort staturerecombinant human growth hormoneinsulin-like growth factor-1PEG-recombinant human growth hormoneadverse event
维普
万方数据
